Methylphenidate for the treatment of Parkinson disease and other neurological disorders

Clinical Neuropharmacology

Volumn 32, Issue 2, 2009, Pages 75-81

  Auriel, Eitan ^a   Hausdorff, Jeffrey M ^a,b,c   Giladi, Nir ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Gait; Methylphenidate; Parkinson disease

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANXIETY; APATHY; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; DELIRIUM; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DRUG ABSORPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DYSKINESIA; DYSPHORIA; HEADACHE; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERTHERMIA; HYPERTHYROIDISM; INSOMNIA; INTRAOCULAR PRESSURE; LEUKOCYTOSIS; MAXIMUM PLASMA CONCENTRATION; MOOD; MOTOR PERFORMANCE; ON OFF PHENOMENON; OUTCOME ASSESSMENT; PAIN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIC; WEIGHT REDUCTION;

CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; METHYLPHENIDATE; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE;

EID: 67651123462     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318170576c     Document Type: Review

References (67)

1. Fahn S, Przedborski S. Parkinsonism. In: Rowland LP, ed. Merritts Neurology: 11th ed. New York: Lippincott, Williams & Wilkins 2005:828-846.
2. Kimko HC, Cross TJ, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37: 457-470.
3. Wesfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics. Online ed. 2006.
4. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-2037.
5. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2003;60:204-211.
6. Pelham WE, Gnagy EM, Maclean LB. Once a day concerta methylphenidate versus three times daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107:105-120.
7. Swanson JM, Cantwell D, Lerner M, et al. Effects of stimulant medication on learning in children with ADHD. J Learn Disabil 1991;24:219-230.
8. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the humane brain. J Neurosci 2001;21:RC121.
9. Volkow ND, Wang G, Fowkler JS, et al. Imaging endogenous dopamine competition with (11C) raclopride in the human brain. Synapse 1994;16:255-262.
10. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998;155:1325-1331.
11. Koochesfahani KM, Fernandez RF, Sossi V, et al. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. Move Disord 2001;21:970-975.
12. Biederman J, Faraone SV. Attention deficit hyperactivity disorder. Lancet 2005;366:237-248.
13. Rappley MD. Clinical practice. Attention deficit - hyperactivity disorders. N Engl J Med 2005;352:165-173.
14. Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention deficit/hyperactivity disorder. Evidence report/technology assessment 11. Rockville, MD: Agency for Healthcare Research and Quality; November 1999. AHRQ publication 00-E005.
15. MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow-up: 24-month outcomes of treatment strategies for attention deficit/hyperactivity disorder. Pediatrics 2004;113:754-761.
16. Biederman J, Spencer T, Wilens T. Evidence based pharmacotherapy for attention deficit with hyperactivity disorders. Int J Neuropsychopharmacol 2004;7:77-97.
17. Pary R, Lewis S, Matushka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry 2002;14:105-111.
18. Okie S. ADHD in adults. N Engl J Med 2006;354:2637-2641.
19. Faraone SV, Spencer T, Aleardi M, et al. Meta analysis of the efficacy of MPH for treating adult attention deficit with hyperactivity Disorders. J Clin Psychopharmacol 2004;24:24-29.
20. Sadock BJ, Sadock VA. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2005:2939-2943.
21. Yogev G, Giladi N, Peretz C, et al. Dual tasking, gait rhythmicity, and Parkinson's disease: which aspects of gait are attention demanding? Eur J Neurosci 2005;22:1248-1256.
22. Allcock LM, Rowan K, Wesnes K. Impaired attention: a risk factor for falls in Parkinson's disease? In: Proceedings of the Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders, June 2007.
23. Yogev-Seligmann GN, Hausdorff JM, Giladi N. The role of executive function and attention in gait. Mov Disord 2008;23: 329-342; quiz 472.
24. Camicioli R, Lea E, Nutt JG, et al. Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 2001;24:208-213.
25. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004;55:766-773.
26. Nut JG, Carter JH, Carlson NE. Effects of methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neuro 2007;64:319-323.
27. Auriel E, Hausdorff JM, Herman T, et al. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006;29:15-17.
28. Hausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil 2001;82:1050-1056.
29. Pollak L, Dobronevsky T, Prokhorov T, et al. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off state. In: Proceedings of the Movement Disorder Society's 11th International Congress of Parkinson's Disease and Movement Disorders, June 2007.
30. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78: 470-475.
31. Gardner RJ, Oliver Munoz S, Fisher L. Mattis Dementia Rating Scale: internal reliability study using a diffusely impaired population. J Clin Neuropsycol 1981;3:271-275.
32. Leitner Y, Barak R, Giladi N, et al. Gait in ADHD: effects of methylphenidate and dual tasking. J Neurol 2007;254:1330-1338.
33. Fahn S, Chatterjee A. Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002;14:4. 461-462.
34. Cantello R, Aguggia M, Gilli M. Analgesic action of methylphenidate on parkinsonian sensory symptoms. Mechanism and pathophysiological implications. Arch Neurol 1988;45:973-976.
35. Bruera E, Fainsinger R, MacEchem T. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992;50:75-77.
36. Fisch RZ. Methylphenidate for medical in-patients. Int J Psychiatry Med 1985;6:75-79.
37. Lavretsky H, Park S, Siddath P, et al. Methylphenidate enhanced antidepressant response to citalopram in the elderly: a double blind placebo controlled pilot trial. Am J Geriatr Psychiatry 2006;14:181-185.
38. Walling VR, Prefferbaum B. The use of methylphenidate in a depressed adolescent with AIDS. J Dev Behav Pediatr 1990;11: 195-197.
39. White JC, Christensen JF, Singer CM. Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: an n-of-1 trial. J Clin Psychiatry 1992;53:153-156.
40. Padala PR, Petty F, Bhatia SC. Methylphenidate may treat apathy independent of depression. Ann Pharmacother 2005;39: 1947-1949.
41. Camacho A, Ng B. Methylphenidate for alpha-interferon induced depression. J Psychopharmacol 2006;20:687-689.
42. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003 1;21:4439-4443.
43. Hanna A, Sledge G, Mayer ML, et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006;14:210-215.
44. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006 1;24:2073-2078.
45. Teixiera AL, Caramelli P. Apathy in Alzheimer's disease. Rev Bras Psiquiatr 2006;28:238-241.
46. Keenan S, Mavaddat N, Iddon J, et al. Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review. Br J Neurosurg 2005;19:46-50.
47. Sjogren M, Minthon L, Passant K, et al. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging 1998;19:379-384.
48. Nagaoka S, Arai H, Iwamoto N, et al. A juvenile case of frontotemporal dementia: neurochemical and neuropathological investigations. Prog Neuropsychopharmacol Biol Psychiatry 1995;19: 1251-1261.
49. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006;31: 651-658.
50. Salmon E, Garraux G, Delbeuck X, et al. Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia. Neuroimage 2003;20:435-440.
51. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;27:855-857.
52. Tardy S, Pariente J, Leger A. Methylphenidate modulates cerebral post-stroke reorganization. Neuroimage 2006;15:913-922.
53. Lou HC, Andresen J, Stienberg B. The striatum in a putative cerebral network activated by verbal awareness in normals and in ADHD children. Eur J Neurol 1998;5:67-74.
54. Grade C, Redford B, Chrostowski J. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-1050.
55. Leonard BE, McCartan D, White J. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004;19:151-180.
56. Sweetman S, ed. Martindale: The Complete Drug Reference. London: Pharmaceutical Press; 2007. Electronic version.
57. Barbic F, Perego F, Canesi M, et al. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 2007;49:120-126.
58. Oka H, Mochio S, Onouchi K, et al. Cardiovascular dysautonomia in de novo Parkinson's disease. J Neurol Sci 2006;241:59-65.
59. Persico AM, Reich S, Henningfield JE, et al. Parkinsonian patients report blunted subjective effects of methylphenidate. Exp Clin Psychopharmacol 1998;6:54-63.
60. Borcherding BG, Keysor CS, Rapoport JL, et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990;33:83-94.
61. Kurlan R. Tourette's syndrome: are stimulants safe? Curr Neurol Neurosci Rep 2003;3:285-288.
62. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58: 527-536.
63. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double blind cross over trial. Psychol Med 2004;34:973-982.
64. Biederman J, Mick E, Surman C, et al. A randomized placebo controlled trial of OROS MPH in adults with attention deficit with hyperactivity disorders. Biol Psychiatry 2006;59:829-835.
65. Wilens TE, Hammereness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2005;66: 253-259.
66. Langendijk PN, Wilde AA. Medication for ADHD and the risk of cardiovascular mortality. Ned Tijdschr Geneeskd 2006;150:1713-1714.
67. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-1448.